[go: up one dir, main page]

UY27645A1 - Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn - Google Patents

Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn

Info

Publication number
UY27645A1
UY27645A1 UY27645A UY27645A UY27645A1 UY 27645 A1 UY27645 A1 UY 27645A1 UY 27645 A UY27645 A UY 27645A UY 27645 A UY27645 A UY 27645A UY 27645 A1 UY27645 A1 UY 27645A1
Authority
UY
Uruguay
Prior art keywords
dispersions
snlid
presinn
mctod
amorphes
Prior art date
Application number
UY27645A
Other languages
English (en)
Inventor
Ronald A Beyerinck
Ray Roderick
Dobry Daniel
Settell Dana
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27645A1 publication Critical patent/UY27645A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Glanulating (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

Dispersiones sólidas amorfas homogéneas de fármacos en polímeros mejoradores de la concentración se preparan en tamanos de partícula más grande adecuadas con minimo contenido de finos, utilizando un atomizador y condiciones de procedimiento capaces de producir gotas que tienen un diámetro medio de al menos 50 micrones y un D10 de al menos 10 micrones.
UY27645A 2002-02-01 2003-01-31 Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn UY27645A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35398602P 2002-02-01 2002-02-01

Publications (1)

Publication Number Publication Date
UY27645A1 true UY27645A1 (es) 2003-09-30

Family

ID=27663274

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27645A UY27645A1 (es) 2002-02-01 2003-01-31 Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn

Country Status (20)

Country Link
US (1) US7780988B2 (es)
EP (1) EP1469830A2 (es)
JP (1) JP2005523260A (es)
KR (1) KR100758045B1 (es)
CN (1) CN1787808A (es)
AR (1) AR038369A1 (es)
AU (1) AU2003239463B2 (es)
BR (1) BR0307515A (es)
CA (1) CA2474958A1 (es)
GT (1) GT200300024A (es)
MX (1) MXPA04007435A (es)
PA (1) PA8565401A1 (es)
PE (1) PE20030804A1 (es)
PL (1) PL371593A1 (es)
RS (1) RS67304A (es)
RU (1) RU2288703C2 (es)
TW (1) TW200404576A (es)
UY (1) UY27645A1 (es)
WO (1) WO2003063821A2 (es)
ZA (1) ZA200405971B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CA2474958A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
WO2003063822A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US7645876B2 (en) 2004-12-01 2010-01-12 TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság Processes for producing crystalline macrolides
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE602005019509D1 (de) 2004-06-01 2010-04-08 Teva Gyogyszergyar Zartkoeruen Verfahren für die zubereitung der amorphen form eines medikamentes
CN104788328B (zh) 2004-06-24 2017-09-12 沃泰克斯药物股份有限公司 Atp‑结合弹夹转运蛋白的调控剂
WO2006079921A2 (en) * 2005-01-28 2006-08-03 Pfizer Products Inc. Drying of drug-containing particles
US20070026073A1 (en) 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
AU2006328385B2 (en) * 2005-12-21 2011-08-25 Eisai R & D Management Co., Ltd. Amorphous form of 1,2-dihydropyridine compound
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
BRPI0707584A2 (pt) 2006-02-09 2011-05-10 Merck & Co Inc composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica
ES2372983T3 (es) 2006-06-06 2012-01-30 Tibotec Pharmaceuticals Proceso para preparar formulaciones secadas por aspersión de tmc125.
WO2008012617A1 (en) 2006-07-21 2008-01-31 Pfizer Products Inc. Drying of drug-containing particles
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US10189957B2 (en) 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
EP2093225A1 (en) 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing crystalline eletriptan hydrobromide form ß
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
US9724664B2 (en) * 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process
EP2813220A3 (en) 2010-04-09 2015-06-17 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
US8557995B2 (en) 2010-06-09 2013-10-15 Abbvie Inc. Solid dispersions containing kinase inhibitors
JP5847813B2 (ja) 2010-06-23 2016-01-27 シマベイ セラピューティクス， インコーポレーテッド ５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
EP2618924A1 (en) * 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
WO2012094381A2 (en) 2011-01-05 2012-07-12 Hospira, Inc. Spray drying vancomycin
TWI520732B (zh) * 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
PT106063B (pt) * 2011-12-19 2017-05-30 Inst Superior Tecnico Minociclina cristalina termorresistente produzida por recristalização com dióxido de carbono
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
CN104321059A (zh) 2012-05-31 2015-01-28 默沙东公司 食欲素受体拮抗剂的固体剂量制剂
CN105358535B (zh) * 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CA2899032A1 (en) 2013-02-01 2014-08-07 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN103694903B (zh) * 2013-12-02 2015-07-01 南通瑞普埃尔生物工程有限公司 一种瞬干胶粘剂及其制备方法
WO2015082562A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
CA2966517C (en) * 2014-07-25 2021-03-16 Laurent Pharmaceuticals Solid oral formulation of fenretinide
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
US9701639B2 (en) 2014-10-07 2017-07-11 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US11364203B2 (en) 2014-10-31 2022-06-21 Bend Reserch, Inc. Process for forming active domains dispersed in a matrix
PL3226841T3 (pl) 2014-12-05 2025-03-03 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
TWI709403B (zh) 2014-12-05 2020-11-11 美商艾瑞岡醫藥公司 抗癌症組成物（二）
RU2585023C1 (ru) * 2014-12-18 2016-05-27 Общество с ограниченной ответственностью "Нанолек" Способ гранулирования
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US20180110760A1 (en) 2016-10-21 2018-04-26 Glialogix, Inc. Compositions and methods for the treatmentof neurodegenerative and other diseases
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
EP3831381A4 (en) 2018-07-30 2022-05-04 Chugai Seiyaku Kabushiki Kaisha SOLID DISPERSION OF A HYDANTOIND DERIVATIVE
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN114828828A (zh) * 2019-11-06 2022-07-29 曼金德公司 氯法齐明的组合物，含它们的组合，它们的制备方法，含它们的用途和治疗方法
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
CN118948772A (zh) 2019-12-30 2024-11-15 德西费拉制药有限责任公司 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物
TWI899133B (zh) 2019-12-30 2025-10-01 美商迪賽孚爾製藥有限公司 非晶形激酶抑制劑調配物及其使用方法
KR20230097021A (ko) 2020-09-29 2023-06-30 선전 파마신 컴퍼니 리미티드 약학 조성물
KR20250004684A (ko) * 2022-03-25 2025-01-08 선전 파마신 컴퍼니 리미티드 Protac 화합물의 약학적 조성물 및 이의 용도
JPWO2024143501A1 (es) 2022-12-28 2024-07-04

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1131242A (en) 1965-02-18 1968-10-23 Gen Foods Ltd Improvements in or relating to spray-drying apparatus
DE2201111A1 (de) 1971-01-19 1972-07-27 Niro Atomizer As Zerstaeubungstrocknungsvorrichtung zur Herstellung von Pulver,z.B. Milchpulver
IT1025765B (it) 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
DE2741196A1 (de) * 1977-09-13 1979-03-15 Bayer Ag Verfahren zur herstellung von perlpolymeren
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4702799A (en) 1985-09-03 1987-10-27 Nestec S.A. Dryer and drying method
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
US5858409A (en) * 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
DE60039802D1 (de) 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2474958A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

Also Published As

Publication number Publication date
WO2003063821A3 (en) 2003-11-13
AU2003239463B2 (en) 2007-10-18
GT200300024A (es) 2003-09-22
PA8565401A1 (es) 2003-12-10
WO2003063821A2 (en) 2003-08-07
RU2004123639A (ru) 2005-04-20
PL371593A1 (en) 2005-06-27
RS67304A (sr) 2006-10-27
CN1787808A (zh) 2006-06-14
RU2288703C2 (ru) 2006-12-10
PE20030804A1 (es) 2003-09-19
US7780988B2 (en) 2010-08-24
JP2005523260A (ja) 2005-08-04
CA2474958A1 (en) 2003-08-07
KR20040083491A (ko) 2004-10-02
AR038369A1 (es) 2005-01-12
EP1469830A2 (en) 2004-10-27
KR100758045B1 (ko) 2007-09-11
TW200404576A (en) 2004-04-01
BR0307515A (pt) 2004-12-07
ZA200405971B (en) 2006-05-31
MXPA04007435A (es) 2004-10-11
US20030185893A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
UY27645A1 (es) Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn
ATE304349T1 (de) Herstellungsverfahren von submikrometerwirkstoffpartikeln
WO2008129106A3 (es) Nanopartículas que comprenden una ciclodextrina y una molécula biológicamente activa y sus aplicaciones
EP2283822A3 (en) Spray drying processes for forming solid amorphous dispersions of drugs and polymers
WO2009095562A3 (fr) Biomateriau permettant la delivrance controlee d'actifs
WO2007116954A3 (en) Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
WO2008011177A3 (en) Medicinal delivery system and related methods
MY159380A (en) Controllable filler prefloculation using a dual polymer system
DE60107872D1 (de) Herstellung von wirkstoffpartikeln durch evaporation-präzipitation in wässrige lösungen
WO2006085101A3 (en) Pharmaceutical compositions useful in the transmucosal administration of drugs
BRPI0411835A (pt) processo para a preparação de partìculas esféricas
WO2007033372A3 (en) Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
SG170087A1 (en) Pharmaceutical compositions
WO2004032849A3 (en) Methods of administering fgf18
MXPA05007154A (es) Atomizador prepeliculizacion.
EA200600877A1 (ru) Наночастицы для доставки лекарств
MX2009005696A (es) Nanoparticulas magneticas para la aplicacion en hipertermia, preparacion de las mismas y uso en constructos que tienen una aplicacion farmacologica.
WO2007141344A3 (fr) Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
EP1847260A3 (en) Solid dispersion preparation
WO2008099615A1 (ja) 微粒子油性懸濁液を含む医薬組成物
EP1847257A3 (en) Solid preparation comprising enteric solid dispersion
WO2008143239A1 (ja) 結晶性微粉化粒子
TW200704750A (en) Functional organic particle, and method for preparing the same
MX2009005947A (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas.
WO2010014176A3 (en) Preparation method of biodegradable micro-particles containing drugs

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126